Today: 7 February 2026
Subscribe
Browse Category

NYSE:BMY News 16 December 2025 - 27 December 2025

Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus

Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus

NEW YORK, Dec. 27, 2025, 5:15 p.m. ET — Market closed Bristol-Myers Squibb Company (NYSE: BMY) heads into the final week of 2025 with U.S. markets shut for the weekend and investor attention shifting to what could matter most when trading resumes Monday: year-end positioning, the company’s next dividend timeline, the next earnings checkpoint, and a set of 2026 regulatory and pipeline milestones that could influence sentiment around the stock. Where BMY stock stands heading into the last trading days of 2025 BMY shares finished the most recent session (Friday) at about $54.65, essentially flat on the day, and later
27 December 2025
···
Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open

Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open

NEW YORK, Dec. 27, 2025, 3:10 p.m. ET — Market closed Bristol-Myers Squibb Company (NYSE: BMY) stock is heading into the weekend with U.S. equity markets closed, leaving investors to digest the latest batch of institutional ownership updates and re-check near-term catalysts that could matter when trading resumes Monday. The pharmaceutical giant finished the most recent regular session (Friday) essentially flat, while broader benchmarks also showed little movement—typical of late-December, liquidity-thinner trading. Bristol Myers Squibb Investors BMY stock price recap: where shares last traded BMS’ investor relations quote page shows BMY at $54.64 as of Dec. 26 at 4:00 p.m.
27 December 2025
·
Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb Company (NYSE: BMY) heads into Dec. 25, 2025 with its stock anchored in the mid-$50s — and with investors juggling two competing storylines: With U.S. markets effectively pausing for the holiday, the most recent available NYSE quote showed BMY around $54.71 (last trade timestamp recorded Dec. 24), after trading between roughly $54.20 and $54.75 intraday. Bristol Myers Squibb Investors Bristol-Myers Squibb stock price today: where BMY stands into Dec. 25, 2025 BMS’s own investor quote page showed BMY at $54.71 on Dec. 24 (delayed quote), with a prior close listed as $54.28 and a 52-week range of $42.52
25 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb Company (NYSE: BMY) ended the Christmas Eve session with a modest gain—and then stayed largely quiet in after-hours trading as U.S. markets wrapped an early close and investors looked ahead to the next full session on Friday, Dec. 26 (U.S. markets are closed on Christmas Day, Dec. 25). New York Stock Exchange Even with the calm tape, today’s coverage of BMY wasn’t short on strong opinions: several market commentators leaned into the “value + dividend” case, while others argued the stock is now closer to fair value after a year-end rebound and policy headlines around Eliquis pricing. chartmill.com
25 December 2025
··
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 23, 2025: Key News, Analyst Forecasts, and What to Watch Before the Dec. 24 Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 23, 2025: Key News, Analyst Forecasts, and What to Watch Before the Dec. 24 Market Open

Bristol-Myers Squibb Company (NYSE: BMY) ended Tuesday, December 23, 2025, slightly lower in regular trading, then steadied after the closing bell as investors digested a fresh legal headline tied to U.S. drug pricing—plus a growing list of end‑of‑year catalysts that could shape sentiment into 2026. BMY finished the session at $54.26, down $0.41 (-0.74%), and traded modestly higher in extended hours at about $54.36 (+0.20%) as of the evening update. MarketBeat After-hours snapshot: where BMY stands tonight Even with the post-close bounce, Tuesday’s tape looked like a classic pre-holiday setup: a narrow move, lighter conviction, and investors focusing more on
24 December 2025
·
Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) stock is back in the spotlight on Tuesday, December 23, 2025, as investors weigh a fast-moving U.S. drug-pricing landscape, fresh legal headlines tied to Medicare negotiations, and new analyst commentary on competitive pressure in a key growth product category. At the same time, Bristol Myers is heading into 2026 with a higher dividend, a defined near-term calendar (including a February earnings date), and intensifying debates over whether the stock’s “value” profile is a bargain—or a reflection of policy risk and the post-patent “reset” that still hangs over Big Pharma. BMY stock price today (December 23,
23 December 2025
··
Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb Company (NYSE: BMY) ended Monday’s regular session on a modestly stronger note, then held near flat in after-hours trading as investors continued to weigh a fast-evolving U.S. drug-pricing landscape, BMS’s Eliquis-focused policy commitments, and a fresh dividend hike headed into 2026. Below is what’s moving BMY after the bell on December 22, 2025, and the key items investors will be watching into Tuesday’s open (Dec. 23)—including the latest headlines, Wall Street forecasts, and the open questions that could drive the next leg up or down. BMY stock after the bell: where shares closed and how after-hours trading looks
23 December 2025
··
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead. Christmas week trading: shorter sessions, fewer buyers, faster
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3 Below is a comprehensive roundup of the most market-moving healthcare news, plus the latest forecasts and sector analysis shaping how investors are positioning across pharma, biotech, managed care, medtech, and healthcare services into 2026. 1) Drug pricing is
20 December 2025
········
Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on Tuesday, December 16, 2025, as investors weigh a fresh Bank of America upgrade, a renewed value debate around the stock’s multiple, and a growing list of 2026 pipeline catalysts that could shape the post–patent-cliff narrative. As of 2:00 p.m. (quotes delayed), BMY shares were $53.66, down 1.15% on the session, with a 52‑week range of $42.52 to $63.33. Bristol Myers Squibb BMY stock today: Where shares are trading and what that implies The mid‑$50s trading zone matters because it has become the market’s “battleground price” between two competing views:
16 December 2025
·
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on December 16, 2025, with the stock trading around $54.29, up roughly 3.6% on the session as optimism builds around Wall Street upgrades, a newly announced dividend increase, and a steady drumbeat of pipeline and regulatory updates heading into 2026. Smartkarma While BMY has spent much of the past year wrestling with familiar big-pharma headwinds—generic erosion in legacy products and a looming “patent cliff” narrative—the last several weeks have looked more like a sentiment reset than a victory lap. One analysis notes a ~16% move over the last 30 days
16 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is ending Monday’s session in the spotlight after a sharp, analyst-driven move that pushed the pharma giant higher into the close — and kept the shares firm in extended trading. After the closing bell on Monday, December 15, 2025, BMY was up about 3.6% in regular trading and added roughly another 0.6% after hours, as investors digested a bullish call from Bank of America and looked ahead to a potentially volatile macro catalyst before Tuesday’s open. MarketWatch Below is what moved the stock, what analysts are forecasting now, and the key items worth watching before
16 December 2025
··
1 2 3

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop